Erasca, Inc.

ERAS · Nasdaq · SIC 2834: Pharmaceutical Preparations
81
SEC Filings

Business Summary

. Overview At Erasca, our name is our mission: to eras e ca ncer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for more than five million new patients diagnosed with cancer globally each year. Our compan...

Next Earnings

Q2 FY2026 — expected 2026-08-11

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionERASdiscussed_in_filing Cybersecurity
topic_mentionERASdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-122025-12-310001193125-26-104150EDGAR103K words
2025-03-202024-12-310000950170-25-042682EDGAR—
2024-03-272023-12-310000950170-24-037193EDGAR—
2023-03-232022-12-310000950170-23-009496EDGAR—
2022-03-242021-12-310000950170-22-004557EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001193125-25-277625EDGAR27K words
2025-08-122025-06-300001193125-25-178996EDGAR—
2025-05-132025-03-310000950170-25-070418EDGAR—
2024-11-122024-09-300000950170-24-125481EDGAR—
2024-08-122024-06-300000950170-24-095437EDGAR—
2024-05-082024-03-310000950170-24-055668EDGAR—
2023-11-092023-09-300000950170-23-062094EDGAR—
2023-08-102023-06-300000950170-23-041333EDGAR—
2023-05-152023-03-310000950170-23-022282EDGAR—
2022-11-092022-09-300000950170-22-023926EDGAR—
2022-08-112022-06-300000950170-22-016907EDGAR—
2022-05-122022-03-310000950170-22-009720EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-120001193125-26-104105EDGAR3K words
2026-01-290001193125-26-029467EDGAR—
2026-01-220001193125-26-019651EDGAR—
2026-01-200001193125-26-016556EDGAR—
2026-01-120001193125-26-009820EDGAR—
2025-11-120001193125-25-277571EDGAR—
2025-08-120001193125-25-178950EDGAR—
2025-06-260000950170-25-090493EDGAR—
2025-05-130000950170-25-070336EDGAR—
2025-03-200000950170-25-042659EDGAR—

81 total filings indexed. 54 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001761918
TickerERAS
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 7ae80891b5e242e2429e9e492d0e7ae890af3cf23c25f26d11ed9b8aa4cdc06b
parent: a0104dcbe28f0b59d80235b5025c8ff59b88f2fd1ceca9f62771729c346dd143
content hash: 34d552329e8d995940b2e33e0c3b28fad3418b156e19b4041037804de4b4bd42
signed: 2026-04-13T04:44:53.741Z
sources: 17 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf